pharmaphorum November 11, 2022
Phil Taylor

The lack of diversity in clinical trials has been a topic of debate for decades, but was thrust into the spotlight as the impact of the pandemic on poorer, less educated, and ethnically diverse populations became ever more apparent. So, has the situation started to improve?

Sadly not, says a new report from IQVIA, which looked specifically at the inclusion of Black/African Americans and Hispanics in clinical trials in recent years. Overall, inclusion of both groups falls well short of the 2020 US demographic level of 13.6% for Black/African Americans and 18.9% for Hispanics.

IQVIA’s research has been helped by a “dramatic increase” in diversity data collection in phase 2 and 3 trials in the past six years, which has...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Clinical Trials, Equity/SDOH, Healthcare System, Survey / Study, Trends
Challenges in Trial Access and Treatment for Women with Chronic Illnesses
Brainomix AI shows its worth in AZ pulmonary fibrosis trial
Moderna moves three vaccines into final stage trials as it works to rebound from Covid slump
'From Interpretation to Action': Using CGM to Manage T2D
Oncology in 2024: The clinical trial trends reshaping the role of CROs

Share This Article